Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer

被引：0
|
作者：
Zhou, J. [1 ]
Zong, Y. [1 ]
Yuan, J. [1 ]
Peng, Z. [1 ]
Lu, M. [1 ]
Wang, X. [1 ]
Shen, L. [1 ]
机构：
[1] Beijing Canc Hosp, Dept Gastrointestinal Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
194P
引用
收藏
页码：S1315 / S1315
页数：1
相关论文
共 50 条
  • [21] Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
    Di Costanzo, Francesco
    Di Costanzo, Federica
    Antonuzzo, Lorenzo
    Mazza, Ernesto
    Giommoni, Elisa
    CANCERS, 2023, 15 (02)
  • [22] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    P. G. Corrie
    W. Qian
    B. Basu
    J. W. Valle
    S. Falk
    C. lwuji
    H. Wasan
    D. Palmer
    M. Scott-Brown
    J. Wadsley
    S. Arif
    J. Bridgewater
    D. Propper
    R. Gillmore
    A. Gopinathan
    R. Skells
    P. Bundi
    R. Brais
    K. Dalchau
    L. Bax
    A. Chhabra
    A. Machin
    A. Dayim
    K. McAdam
    S. Cummins
    L. Wall
    R. Ellis
    A. Anthoney
    J. Evans
    Y. T. Ma
    C. Isherwood
    A. Neesse
    D. Tuveson
    D. I. Jodrell
    British Journal of Cancer, 2020, 122 : 1760 - 1768
  • [23] Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.
    Sun, Yongkun
    Zhou, Ai-Ping
    Zhang, Wen
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [25] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [26] First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
    Vogel, Arndt
    Pelzer, Uwe
    Salah-Eddin, Al-Batran
    Koester, Wolf
    IN VIVO, 2014, 28 (06): : 1135 - 1140
  • [27] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [28] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [29] AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER
    Hollmann, S.
    Alloul, K.
    Attard, C.
    Kavan, P.
    ANNALS OF ONCOLOGY, 2014, 25 : 11 - 11
  • [30] Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer
    Li, Xiaofen
    Zhou, Nan
    Yang, Yu
    Lu, Zijian
    Gou, Hongfeng
    CANCER SCIENCE, 2024, 115 (07) : 2371 - 2383
12345